Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mahamaya LifesciencesBOM:544611 16 Days Payable is 80.51 as of Mar. 2026, which is 18% above its 10-year median of 68.10. GuruFocus rates BOM:544611 with a GF Score™ of 16/100. The stock has 4 warning signs investors should review. Among 245 Agriculture companies, Mahamaya Lifesciences ranks better than 84.49% on this metric.
Mahamaya Lifesciences Days Payable Historical Data
* Premium members only.
The historical data trend for Mahamaya Lifesciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544611 vs CTVA, CF, MOS: Days Payable Comparison
For the Agricultural Inputs subindustry, Mahamaya Lifesciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mahamaya Lifesciences Days Payable vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Mahamaya Lifesciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Mahamaya Lifesciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mahamaya Lifesciences's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mahamaya Lifesciences (BOM:544611) has a Days Payable of 80.51 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mahamaya Lifesciences and its competitors. This is 18% above median its historical median of 68.10. Over the past decade, Mahamaya Lifesciences' Days Payable has ranged from 62.55 to 161.02. According to the industry distribution chart, Mahamaya Lifesciences ranks #38 out of 245 companies in the Agriculture industry, placing it in the top 15.5%.
Is Mahamaya Lifesciences' Days Payable too high?
Mahamaya Lifesciences' current Days Payable of 80.51 is 18% above median its 10-year median of 68.10. Over the past 10 years, this metric has ranged from a low of 62.55 to a high of 161.02. The Agriculture industry median Days Payable is 72.56. Mahamaya Lifesciences' value of 80.51 is 11% above this industry median. Based on the distribution chart, Mahamaya Lifesciences ranks #38 out of 245 companies in the Agriculture industry, which is in the top quartile — a strong position relative to peers. Overall, Mahamaya Lifesciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Mahamaya Lifesciences' Days Payable compare to CTVA and CF?
According to the Agriculture industry distribution chart, Mahamaya Lifesciences ranks #38 out of 245 companies for Days Payable. This places Mahamaya Lifesciences in the top 16% of its industry — outperforming the majority of peers. The industry median Days Payable is 72.56. Mahamaya Lifesciences' value of 80.51 is 11% above this benchmark. Historically, Mahamaya Lifesciences' own Days Payable has ranged from 62.55 to 161.02 over the past decade. While the company's 10-year median is 68.10 vs. the industry median of 72.56, Mahamaya Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for an Agriculture company?
The median Days Payable among Agriculture companies is 72.56, based on 245 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mahamaya Lifesciences's current Days Payable of 80.51 is 11% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mahamaya Lifesciences and its competitors. For the Agriculture industry, the median Days Payable is 72.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mahamaya Lifesciences's current Days Payable is 80.51, which is 18% above median its own 10-year median of 68.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mahamaya Lifesciences stock overvalued right now?
Mahamaya Lifesciences (BOM:544611) has a current Days Payable of 80.51. The current Days Payable is 80.51, which is 18% above median its 10-year median of 68.10 and 11% above the Agriculture industry median of 72.56. Mahamaya Lifesciences' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mahamaya Lifesciences (BOM:544611), the current Days Payable is 80.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mahamaya Lifesciences Ltd specializes in the manufacturing of pesticide formulations and supplies bulk formulations catering to both Indian agrochemical companies as well as multinational corporations (MNCs). The company's offerings include Insecticides, Herbicides, and Fungicides. Geographically, it serves multiple Indian states including Punjab, Haryana, Rajasthan, and Uttar Pradesh, and internationally serves countries like the Dominican Republic, Turkey, Egypt, and the UAE. The company generates revenue from the sale of its pesticide formulations.
16GF Score
Get the complete analysis for BOM:544611
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544611 has been successfully added to your 
